ChemoCentryx Inc (CCXI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

ChemoCentryx Inc (CCXI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH140080D
  • |
  • Pages: 47
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

ChemoCentryx Inc (ChemoCentryx) is a biopharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company's pipeline products include C5aR programs, CCR2 program, CCR9 program, and CCR1 program. ChemoCentryx's C5aR Program is for the treatment of anti-neutrophil cytoplasmic antibody associated renal vasculitis. The company's CCR2 Program provides CCX140 for the treatment of diabetic nephropathy, a form of kidney disease and CCX872 for the treatment of pancreatic cancer. Its CCR9 Program is for the treatment of patients with Crohn's disease and CCX507 is for the treatment of inflammatory bowel disease. ChemoCentryx is headquartered in Mountain View, California, the US.

ChemoCentryx Inc (CCXI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deal Details 11

Licensing Agreements 11

Vifor Pharma Expands Licensing Agreement with ChemoCentryx 11

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 12

GlaxoSmithKline Exercises Option For Licensing Agreement With ChemoCentryx For CCX354 13

Equity Offering 14

ChemoCentryx Completes Public Offering Of Common Stock For USD69 Million 14

ChemoCentryx Completes IPO Of Common Stock For USD45 Million 15

ChemoCentryx Completes Private Placement Of Shares For USD5 Million 17

ChemoCentryx Announces Private Placement For USD7 Million 18

ChemoCentryx Inc-Key Competitors 19

Key Employees 20

Locations And Subsidiaries 21

Head Office 21

Other Locations & Subsidiaries 21

Recent Developments 22

Financial Announcements 22

May 10, 2017: ChemoCentryx Reports First Quarter 2017 Financial Results 22

Mar 14, 2017: ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results 23

Nov 07, 2016: ChemoCentryx Reports Third Quarter 2016 Financial Results and Provides Corporate Update 24

Aug 08, 2016: ChemoCentryx Reports Second Quarter 2016 Financial Results and Provides Corporate Update 26

May 10, 2016: ChemoCentryx Reports First Quarter 2016 Financial Results and Provides Corporate Update 28

Mar 14, 2016: ChemoCentryx Reports Fourth Quarter 2015 Financial Results and Provides Corporate Update 30

Corporate Communications 32

Oct 20, 2016: ChemoCentryx Appoints Henry A. McKinnell, Jr. to Board of Directors 32

Government and Public Interest 33

Oct 17, 2016: FDA awards 21 grants to stimulate product development for rare diseases 33

Product News 35

Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy 35

Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 36

Product Approvals 37

Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 37

Clinical Trials 38

Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials ('CLEAR' and 'CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 ('Avacopan') 38

Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016 39

Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 41

May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 43

Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 45

Appendix 47

Methodology 47

About GlobalData 47

Contact Us 47

Disclaimer 47

List of Figures

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

List of Tables

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

ChemoCentryx Inc, Deals By Therapy Area, 2011 to YTD 2017 9

ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Vifor Pharma Expands Licensing Agreement with ChemoCentryx 11

Vifor Pharma Enters into Licensing Agreement with ChemoCentryx for CCX168 12

GlaxoSmithKline Exercises Option For Licensing Agreement With ChemoCentryx For CCX354 13

ChemoCentryx Completes Public Offering Of Common Stock For USD69 Million 14

ChemoCentryx Completes IPO Of Common Stock For USD45 Million 15

ChemoCentryx Completes Private Placement Of Shares For USD5 Million 17

ChemoCentryx Announces Private Placement For USD7 Million 18

ChemoCentryx Inc, Key Competitors 19

ChemoCentryx Inc, Key Employees 20

ChemoCentryx Inc, Subsidiaries 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

ChemoCentryx Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16190
Site License
USD 500 INR 32380
Corporate User License
USD 750 INR 48570

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com